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Abstract
Invasive amebic diseases caused by Entamoeba histolytica are increasing among men who have sex with men and co-
infection of ameba and HIV-1 is an emerging problem in developed East Asian countries. To characterize the clinical and
epidemiological features of invasive amebiasis in HIV-1 patients, the medical records of 170 co-infected cases were analyzed
retrospectively, and E. histolytica genotype was assayed in 14 cases. In this series of HIV-1-infected patients, clinical
presentation of invasive amebiasis was similar to that described in the normal host. High fever, leukocytosis and high CRP
were associated with extraluminal amebic diseases. Two cases died from amebic colitis (resulting in intestinal perforation in
one and gastrointestinal bleeding in one), and three cases died from causes unrelated to amebiasis. Treatment with
metronidazole or tinidazole was successful in the other 165 cases. Luminal treatment was provided to 83 patients following
metronidazole or tinidazole treatment. However, amebiasis recurred in 6 of these, a frequency similar to that seen in
patients who did not receive luminal treatment. Recurrence was more frequent in HCV-antibody positive individuals and
those who acquired syphilis during the follow-up period. Various genotypes of E. histolytica were identified in 14 patients
but there was no correlation between genotype and clinical features. The outcome of metronidazole and tinidazole
treatment of uncomplicated amebiasis was excellent even in HIV-1-infected individuals. Luminal treatment following
metronidazole or tinidazole treatment does not reduce recurrence of amebiasis in high risk populations probably due to
amebic re-infection.
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Introduction
Invasive amebiasis (IA) caused by Entamoeba histolytica is the
second most common cause of mortality associated with parasitic
infections worldwide, accounting for 40,000 to 100,000 deaths
annually [1]. Amebiasis is transmitted by ingestion of food or
water containing the cyst form of E. histolytica, which is prevalent in
developing countries in Central and South America, Asia, and
Africa. In the developed countries, most cases arise in travelers and
immigrants from such endemic areas [2]. Recently, however, three
developed East Asian countries (Japan, Taiwan, and South Korea)
reported increased risk for amebiasis among men who have sex
with men (MSM) due to oral-anal sexual contact [3–12]. The
annual incidence of human immunodeficiency virus type 1 (HIV-
1) infection is also increasing among MSM in these countries [13-
17], resulting in growing concern on IA in HIV-1-infected MSM
[6,9–12,18]. The recommended treatment for IA is metronidazole
(750 mg t. i. d. for 10 days) or tinidazole (2 g q. d. for 3 days),
followed by a luminal agent (paromomycin 500 mg t. i. d. for 10
days or diloxanide furoate 500 mg t. i. d. for 10 days) to eliminate
intestinal colonization [18,19]. A previous report described no
difference in the response to metronidazole or tinidazole treatment
between HIV-1-positive and –negative IA patients [20]. However,
the efficacy of luminal treatment in preventing recurrence, which
can arise by relapse or re-infection, has not yet been assessed
rigorously. In this study, we retrospectively analyzed 170 HIV-1-
infected Japanese patients with IA, together with genomic typing
of E. histolytica in 14 of these patients, and delineated the clinical
features of IA in HIV-1-infected individuals and the efficacy of
metronidazole, tinidazole and luminal treatment.
Methods
Ethics statement
The Institutional Review Board of National Center for Global
Health and Medicine (Tokyo, Japan) approved this study. All
patients who provided clinical samples for genotyping of E.
histolytica gave written informed consent.
Case review
The medical records of HIV-1-infected cases diagnosed with IA
at the AIDS Clinical Center, National Center for Global Health
and Medicine, between April 1997 and March 2010, were
reviewed. The diagnosis of IA was made when one of the following
criteria was satisfied; 1) identification of and/or positive PCR
(methods; see below) in clinical specimens (stool or punctuate-
exudate) for erythrophagocytic trophozoites in patients with IA-
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diarrhea, 2) high serum titer (.1:100) for antibody against E.
histolytica in patients with IA-related symptoms in whom microbi-
ological cultures or histological examination of clinical specimens
did not identify any pathogen, and who showed improvement of
IA symptoms following metronidazole or tinidazole monotherapy
[10–12]. The medical records were surveyed for patients’
characteristics, presenting forms of clinical IA [e.g., colitis, amebic
liver abscess (ALA), and perianal abscess], HIV-1-induced
immunocompromised status, and symptoms, laboratory data and
serological markers of other sexually-transmitted diseases (STD)
including syphilis, hepatitis B and C viruses (HBV and HCV).
After completion of treatment for IA, the medical records were
followed-up until March 2010, excluding those cases found to have
died or lost to follow-up.
Genotyping of E. histolytica
To determine the strains of E. histolytica among HIV-1-infected
Japanese patients, genotyping of E. histolytica was performed in
patients who were PCR positive. The PCR method was used for the
first time in our clinic for the diagnosis of amebiasis in December
2008, and since then 14 patients had been diagnosed as IA based on a
positive PCR. For the PCR, DNAs were extracted from various
biological specimens (e.g., stool, colon wash and punctuate-exudate)
by using QIAamp DNA stool Mini Kit (Qiagen, Valencia, CA).
Polymerase chain reactions were performed with specific sets of
primers designed to target each of 6 loci (D-A, S-Q, R-R, A-L, S
TGA-
D, and N-K) of tRNA-linked polymorphic short tandem repeats
(STR), as described previously [21]. The PCR product was
sequenced by ABI 3130XL Genetic Analyzer (Applied Biosystem,
Foster city, CA) in both forward and reverse directions. Phylogenetic
analysis and genotyping wereperformed as described previously [22].
Statistical analysis
Differences in patients’ characteristics and clinical features were
examined using the chi-square test or nonparametric test. The
cumulative risk for recurrence was analyzed by the Kaplan-Meier
method, and differences were tested by the log-rank test. The Cox
proportionalhazards model was used to assessthe impactof luminal
treatment on the recurrence rate after adjustment for other factors.
The hazard ratio and 95% confidence interval were calculated. P
values less than 0.05 were considered to denote statistical
significance. All statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS Inc., Chicago, IL).
Results
Clinical data and response to treatment
IA was diagnosed in 170 HIV-1-infected cases between April
1997 and March 2010 (including amebic colitis, n=102; ALA,
n=63; and perianal abscess, n=5, Table 1). Thirty-three patients
had two of the above three clinical forms of IA. All patients were
males and 164/170 (96.5%) were MSM. High rates of positive
TPHA (Treponema pallidum hemagglutination assay) (71.2%) and
HBV exposure (HBs antigen-positive, HBs antibody-positive, or
HBc antibody-positive) (60.0%) were observed. No significant
differences were seen in CD4 counts, HIV-1 loads, coexisting AIDS
definite disease and the proportion of patients treated with
antiretrovirals, suggesting that HIV-induced immunocompromised
status did not have an impact on the clinical presentation of amebic
infection, in agreement with previous data [12]. In cases of amebic
colitis (n=102), diarrhea (69.7%) was the most common symptom
followed by dysentery (55.9%) (Table 2). Fever (.37.5uC) was seen
in only 20 patients (19.6%), including 5 cases with perforative
peritonitis. In cases with ALA (n=63), fever (95.2%) was the most
common symptom followed by abdominal pain (55.6%). Diarrhea
(46.0%) and dysentery (19.0%) were only seen in less than half of
ALAcases.Single abscess(72.6%)wasidentifiedinmost cases.Liver
abscesses were seen more frequently in the right lobe (70.5%) than
the left (9.8%). Nine patients (14.3%) had pleuritis (considered a co-
existing disease), as well as abscesses in the right lobe, and 7 of these
presented chest pain. Comparison of physical and laboratory data
showed higher peak body temperature (BT), leukocyte count and C
reactive protein (CRP) in ALA cases (Table 2) and perforative
peritonitis cases (data not shown) compared with colitis cases,
indicating that high fever, leukocytosis and high CRP could be the
signs of extraluminal amebiasis. It is reported that high fever and
leukocytosis are also common in ALA patients free of HIV-1
infection, though both parameters were unusually associated with
simple amebic colitis [23]. In ALA cases, however, leukocyte count
correlated positively with CD4 count (data not shown in tables:
Pearson product-momentcorrelation coefficient 0.36,p value 0.004)
and negatively with HIV-RNA load (Pearson product-moment
correlation coefficient -0.28, p value 0.03), but CRP correlated
neither with CD4 count nor HIV-RNA load (CRP-CD4, p=0.81,
CRP-HIV-RNA, p=0.32). There were also no correlations
between CD4 count, HIV-RNA load, BT, leukocyte count or
CRP and abscess size or number.
All patients were treated with metronidazole (750 mg t. i. d. for
10 days) for IA, with the exception of two who were treated with
tinidazole (2 g q. d. for 3 days). Complete remission of all IA
symptoms was observed in 165 patients including the two treated
with tinidazole. Five cases died within six months after diagnosis of
IA; two from complications related to amebic colitis (one
peritoneal perforation and one gastrointestinal bleeding), one
from malignant lymphoma, one from Pneumocystis jirovecii pneu-
monia, and one from pulmonary thrombosis. The overall
mortality rate was 3% in this study, which was comparable to
those reported in non-HIV cases [2,23].
Recurrence after treatment
Luminal agents; paromomycin and diloxanide, are not approved
in Japan, and they were not always available in our facility during
the study period. After completion of IA treatment with
metronidazole or tinidazole, luminal agents were administered
when available. Consequently, 83 cases were treated with luminal
Author Summary
Amebiasis is usually transmitted by ingestion of contam-
inated food or water in developing countries. Recently,
however, increased risk for amebiasis among men who
have sex with men (MSM) due to oral-anal sexual contact
was reported in developed countries, resulting in growing
concern on amebiasis in HIV-1-infected MSM. The recom-
mended treatment of amebiasis is metronidazole or
tinidazole, followed by a luminal agent to eliminate
intestinal cyst colonization. However, the efficacy of
luminal treatment in preventing recurrence has not been
assessed yet. In this study, we analyzed the medical
records of 170 patients with amebiasis and HIV-1 co-
infection. Treatment with metronidazole or tinidazole was
excellent whereas luminal treatment did not reduce the
frequency of recurrence of amebiasis. Recurrence was
more frequent in those MSM with signs of sexual activity
such as syphilis infection. Luminal treatment following
metronidazole or tinidazole treatment does not reduce
recurrence of amebiasis in high risk populations.
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45 cases with diloxanide furoate (500 mg t. i. d. for 10 days). No
significant differences were seen in patients’ characteristics,
including HIV-1-induced immunocompromised status, serological
markers of other STD, and clinical forms and severity of amebiasis
between the 83 cases with luminal treatment and 82 cases who did
notreceive such treatment(Table S1). The median follow-upperiod
after completion of metronidazole or tinidazole treatment was 50
months (inter quartile range: 19–85) in those who received luminal
treatment, and 43 months (inter quartile range: 23–98) in those
without.
Within the 12-month post-metronidazole treatment period,
recurrence of IA was noted in only two patients who did not
receive luminal treatment, suggesting reactivation of residual cysts
of E. histolytica (Figure 1). However, during the entire follow-up
period, six in each group experienced recurrence of IA, with no
significant difference in the recurrence frequency by the log-rank
chi-square test. Multivariate analysis showed that recurrence did
not correlate with past history of IA, CD4 count, TPHA, HBV
exposure (HBs antigen-positive or HBs antibody-positive), or the
presence of extraluminal IA disease (Table 3). However, a positive
HCV antibody was significantly associated with IA recurrence.
Recurrence also tended to occur in those who acquired new
syphilis infection during the follow-up period, though the
difference did not reach statistical significance.
Genotypes of E. histolytica
Genotyping of E. histolytica was performed in samples obtained
from 14 patients between December 2009 and March 2010
(colitis, n=8; ALA, n=4; colitis and ALA, n=1; and perianal
abscess, n=1; Table S2). Eleven different genotypes were
recognized, including five genotypes (J8, J12, J13, J20, and J23)
identified previously in Japan [22], and six newly recognized
genotypes (J24-J29). There was no significant relation between E.
histolytica genotype and clinical presentation.
Discussion
In the present study, retrospective analysis of the medical
records of 170 patients with HIV-1-infection and IA showed no
Table 1. Patient demographics, state of HIV, and serological markers.
Colitis (n=102)
1 ALA (n=63)
2
Perianal abscess
(n=5)
3 All (n=170) P value
4
Age (years) [IQR] 38 [32–43] 37 [31–44] 45 38 [31–44] 0.58
Male sex (%) 102 (100) 63 (100) 5 (100) 170 (100) –
Homosexual (%) 96 (94.1) 63 (100) 5 (100) 164 (96.5) 0.053
Past History of amebiasis (%) 16 (15.7) 9 (14.3) 1 (20.0) 26 (15.3) 0.81
CD4 count (/ml) 262 [98–398] 271 [123–411] 58 269 [107–403] 0.84
HIV-RNA (log copies/ml) 4.60 [3.89–5.32] 4.66 [3.91–5.11] 5.04 4.66 [3.93–5.28] 0.70
AIDS (%) 18 (17.6) 8 (12.7) 2 (40.0) 28 (16.5) 0.40
ART initiated (%) 18 (17.6) 11 (17.5) 1 (20.0) 30 (17.6) 0.98
TPHA test positive (%) 77 (75.5) 40 (63.5) 4 (80.0) 121 (71.2) 0.10
HBV exposure (%) 59 (57.8) 41 (65.1) 2 (40.0) 102 (60.0) 0.36
HCV Antibody positive (%) 3 (2.9) 3 (4.8) 0 (0) 6 (3.5) 0.42
Data are median [interquartile range: IQR] or number (percentage) of patients.
15 cases of perforative peritonitis are included as co-existing diseases. Four cases were diagnosed coincidentally by colonoscopy in asymptomatic patients.
231 cases of colitis, 1 case of perianal abscess, 9 cases of pleuritis, and 2 cases of peritonitis are included as co-existing diseases.
31 case of colitis is included as co-existing diseases.
4Chi-square test or non-parametric test was performed for data of colitis and ALA.
UD: undetectable, ART: anti-retroviral therapy, TPHA test: Treponema pallidum Hemagglutination Assay test, HBV exposure: HBsAg-positive or HBsAb-positive, and/or
HBc-Ab positive.
doi:10.1371/journal.pntd.0001318.t001
Table 2. Clinical features of amoebic colitis and ALA.
Colitis (n=102) ALA (n=63) P value
Symptoms
Diarrhea (%) 71/102 (69.6) 29/63 (46.0) 0.003
Dysentery (%) 57/102 (55.9) 12/63 (19.0) ,0.001
Abdominal pain (%) 23/102 (22.5) 35/63 (55.6) ,0.001
Chest pain (%) 0/102 (0.0) 7/63 (11.1) ,0.001
Peak BT (uC) [IQR]
3 36.8 [36.5–37.4] 39.0 [38.8–39.5] ,0.001
WBC (/m l) [IQR]
3 5,830 [4490–7580] 11,760 [9460–15170] ,0.001
CRP (mg/dl) [IQR]
3 0.62 [0.16–3.02] 19.15 [10.53–24.75] ,0.001
Frequency of diarrhea
1
# 5 times/day (%) 63/101 (62.4) –
6–10 times (%) 26/101 (25.7) –
$ 11 times (%) 12/101 (11.9) –
Size of abscess (mm) – 59 (10–180)
Location of abscess
2
Right lobe only – 43/61 (70.5)
Left lobe only – 6/61 (9.8)
Both lobes – 12/61 (19.7)
Number of abscesses
1
Single (%) – 45/62 (72.6)
Multiple (%) – 17/62 (27.4)
1Data of one case were not available.
2Data of two cases were not available.
3Data are median [interquartile range: IQR] or number (percentage) of patients.
BT: body temperature, WBC: White Blood Cell counts, CRP: C reactive protein.
doi:10.1371/journal.pntd.0001318.t002
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clinical forms of amebiasis. The physical and laboratory findings
showed that high fever, leukocytosis and high CRP correlated with
extraluminal diseases of amebiasis. In ALA cases, however,
leukocyte count correlated positively with CD4 count and
negatively with HIV-RNA load, indicating that CRP is more
sensitive marker for the detection of the extraluminal diseases in
advanced immunocompromised patients.
Only five patients died after the diagnosis of IA; two from IA
complications and three from other causes. The results indicate
excellent outcome for HIV-1-infected individuals with uncompli-
cated amebiasis treated with metronidazole or tinidazole, in
agreement with previous reports on HIV and non-HIV cases
[2,11,12,20,23]. Based on conventional wisdom and written
opinion, adequate management of IA should include treatment
with a luminal agent following metronidazole or tinidazole
treatment, in order to eradicate residual cysts of E. histolytica due
to the high rate (40–60%) of luminal colonization [2,23–27]. On
the other hand, the results of longitudinal observational studies
indicated that asymptomatic cyst carriers rarely develop IA, and
Figure 1. Kaplan-Meier estimates of time to IA recurrence. Cumulative probability of IA recurrence after completion of metronidazole or
tinidazole treatment with or without subsequent luminal treatment.
doi:10.1371/journal.pntd.0001318.g001
Table 3. Multivariate analyses for factors associated with frequency of recurrence.
No recurrence
(n=153)
1 Recurrence (n=12) Hazard ratio (95.0% CI) Pv alue
Past history of IA
2 (%) 24 (15.7) 2 (16.7) 0.914 (0.186–4.478) 0.911
CD4 counts ,200
2 (%) 57 (37.3) 3 (25.0) 0.385 (0.101–1.470) 0.162
TPHA test positive
2 (%) 108 (70.6) 10 (83.3) 2.435 (0.501–11.827) 0.270
HBV exposure
2 (%) 92 (60.1) 7 (58.3) 1.248 (0.364–4.277) 0.725
HCV Antibody positive
2 (%) 3 (2.0) 2 (16.7) 7.664 (1.369–42.890) 0.020
Extraluminal disease
2 (%) 66 (43.1) 4 (33.3) 0.559 (0.163–1.921) 0.356
No luminal agent (%) 76 (49.7) 6 (50.0) 1.070 (0.322–3.559) 0.912
Syphilis during follow-up period (%) 33 (21.6) 7 (58.3) 3.332 (0.961–11.547) 0.059
1Five patients died within 6 months from disease onset and their data were excluded from analysis.
2Status at diagnosis of IA.
doi:10.1371/journal.pntd.0001318.t003
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treatment [28,29]. There is controversy about the need for cyst
eradication following metronidazole or tinidazole treatment,
especially in endemic areas where re-infection is frequent. In this
study, recurrence of IA within the first year of metronidazole
treatment was noted in only two patients of 82 patients who did
not receive luminal therapy. Moreover, long-term follow-up
indicated IA recurrence also in those who received luminal
agents, and the benefits obtained from luminal treatment seemed
to have disappeared. IA recurred more frequently in those with
HCV infection, which was recently reported to be transmittable
sexually among MSM [30], and in those who acquired new
syphilis infection during the follow-up period, suggesting that
sexually active MSM tend to experience IA recurrence due to re-
acquisition of new E. histolytica infection. HBV exposure and
positive TPHA at IA diagnosis did not correlate with IA
recurrence probably because the high prevalence of these two
parameters in this study masked the difference between recurrence
and non-recurrence cases. Educational approach for safer sex may
be more appropriate rather than luminal treatment to prevent IA
recurrence after treatment.
Eleven genetic strains of E. histolytica were identified in this study
and none of them had been reported so far from geographic areas
other than Japan [21,22,31,32], indicating that diverse Japan-
specific isolates of E. histolytica are already prevalent among MSM
in Japan. In fact, the E. histolytica seropositivity rate in HIV-1-
infected MSM in our clinic was as high as 17.9% in 2009
(unpublished data), which is comparable with the seropositivity
rate in Japanese MSM reported more than 20 years ago [5].
Unfortunately, we could not compare the genotypes of E. histolytica
between the incidences of the primary and recurrent IA within the
same individuals due to the lack of appropriate stocked samples,
which would have probably demonstrated acquisition of new
infection.
Considered together, the results emphasize the difficulty of
preventing IA recurrence without educational approach to prevent
new amebic infection even after successful IA treatment in the
high risk groups such as HIV-1-infected MSM. The spread of E.
histolytica in MSM of other developed countries beyond Asia should
be of great concern.
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